AstraZeneca PLC logo

AZN

AstraZeneca PLC

$67.97

Earnings Summary

Revenue
$11390Mn
Net Profits
$386Mn
Net Profit Margins
3.39%

Highlights

Revenue:

AstraZeneca PLC’s revenue jumped 55.6% since last year same period to $11390Mn in the Q1 2022. On a quarterly growth basis, AstraZeneca PLC has generated -5.17% fall in its revenue since last 3-months.

Net Profits:

AstraZeneca PLC’s net profit fell -75.27% since last year same period to $386Mn in the Q1 2022. On a quarterly growth basis, AstraZeneca PLC has generated 211.24% jump in its net profits since last 3-months.

Net Profit Margins:

AstraZeneca PLC’s net profit margin fell -84.11% since last year same period to 3.39% in the Q1 2022. On a quarterly growth basis, AstraZeneca PLC has generated 217.3% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the AstraZeneca PLC post its latest quarter earnings

EPS Estimate Current Quarter
0.75
EPS Estimate Current Year
0.75

Highlights

EPS Estimate Current Quarter:

AstraZeneca PLC’s earning per share (EPS) estimates for the current quarter stand at 0.75 - a -2.11% fall from last quarter’s estimates.

EPS Estimate Current Year:

AstraZeneca PLC’s earning per share (EPS) estimates for the current year stand at 0.75.

Key Ratios

Key ratios of the AstraZeneca PLC post its Q4 2022 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

AstraZeneca PLC’s earning per share (EPS) fell -100% since last year same period to 0 in the Q4 2022. This indicates that the AstraZeneca PLC has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-31
0.85
0.95
11.52%
2023-02-02
0.75
0
-100%

Company Information

AstraZeneca plc is an English pharmaceutical company located in Cambridge. It is a multinational pharmaceutical and biotechnology firm based in the United Kingdom and Sweden. The company operates in over 100 countries and caters to the requirements of millions of people globally. Among the significant ailments covered by the company's product range are oncology, gastrointestinal, infectious, respiratory, and inflammatory disorders. Astra AB and Zeneca Group Plc amalgamated to establish AstraZeneca in 1999. Astra AB was founded in 1913 by 400 Swedish doctors. Zeneca Group PLC was created in 1993 when the British chemicals business ICI (formed by the amalgamation of four British chemical companies) demerged its medicines, agrochemicals, and specialist divisions to become Zeneca Group PLC. The merger is one of the world's largest pharmaceutical businesses, having purchased several corporations, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013), and Definiens (by MedImmune in 2014). The organisation undertakes research and development in three strategic locations: England, Sweden, and Maryland, United States. The Oxford–AstraZeneca vaccine was approved for use in India in January 2021, paving the way for a large-scale vaccination campaign in the world's second-most populous country. The Serum Institute of India later stated that the Oxford–AstraZeneca shot would be manufactured locally under the brand name COVISHIELD. Currently Astrazeneca plc - ADR has a market cap of $204.77 Billion. It has a P.E ratio of 104.12. The shares of Astrazeneca plc - ADR are trading at $67.97. .

Organisation
AstraZeneca PLC
Headquarters
1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA
Employees
83100
Industry
Health Technology
CEO
Pascal Soriot

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*